Article Details

Developing donanemab - balancing cost versus benefit - European Pharmaceutical Review

Retrieved on: 2024-10-24 16:16:38

Tags for this article:

Click the tags to see associated articles and topics

Developing donanemab - balancing cost versus benefit - European Pharmaceutical Review. View article details on hiswai:

Excerpt

Anti-amyloid beta (Aβ) monoclonal antibody (mAb) donanemab is part of new class of amyloid targeting therapies, and while it can slow Alzheimer's ...

Article found on: www.europeanpharmaceuticalreview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up